EGTX.ST

Egetis Therapeutics AB (publ) [EGTX.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

EGTX.ST Stock Summary

Top 10 Correlated ETFs

EGTX.ST

Top 10 Correlated Stocks

EGTX.ST

In the News

EGTX.ST Financial details

Company Rating
-
Market Cap
1.78B
Income
-326.6M
Revenue
57.5M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
03 May 2024
P/E
-4.84
Forward P/E
-
PEG
-1.58
P/S
59.09
P/B
3.29
P/C
-
P/FCF
-6.02
Quick Ratio
1.39
Current Ratio
1.94
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.28
EPS next Y
-
EPS next Q
-
EPS this Y
29.59%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
3.29%
Revenue last 5Y
-6.95%
Revenue Q/Q
167.21%
EPS Q/Q
-14.29%
-
-
-
-
SMA20
33.33%
SMA50
-
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-60%
ROE
-59%
ROC
-0.68%
Gross Margin
-559%
Oper. Margin
-1049%
Profit Margin
-1042%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.8-9.2
52W High
-45%
52W Low
+65%
RSI
66
Rel Volume
1.09
Avg Volume
380.62K
Volume
413.68K
Perf Week
24.69%
Perf Month
51.84%
Perf Quarter
-26.01%
Perf Half Y
-29.29%
-
-
-
-
Beta
1.295
-
-
Volatility
0.24%, 0.6%
Prev Close
4.87%
Price
4.95
Change
7.61%

Something similar

Top by Market Cap
APC.DE
LLY
BRK-B
1YD.DE
LLY.DE
Top Correlated ETFs
DCP.TO
176950.KS
292770.KS
SPESGE.SW
279540.KS
Top Correlated Stocks
NTEK-B.ST
MIPS.ST
0QU6.L
CMTV
MLFDV.PA
Similar Market Cap
MCY
CYYYX
0133.HK
002800.SZ
ZIONP

Company Profile

Healthcare Biotechnology
  • Volume Average 380.62K
  • Market Capitalization 1.78B
  • Employee 29
  • CEO Mr. Nicklas Westerholm
  • Headquarters Stockholm,SE
  • IPO Date 2011-04-07
  • Website https://www.egetis.com

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.